In a significant stride for Alzheimer’s treatment, Anavex Life Sciences has announced compelling results from its recent phase 2b/3 trial of blarcamesine (ANAVEX2-73). Anavex’s investigational therapy has shown promising outcomes in reducing amyloid-ß biomarkers, a critical indicator of neurodegeneration, in patients with early Alzheimer’s disease.   The randomized, double-blind, placebo-controlled study enrolled 508 participants across […]